Analysts Anticipate Opko Health Inc. (OPK) Will Post Quarterly Sales of $262.52 Million
Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will report sales of $262.52 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Opko Health’s earnings. The highest sales estimate is $268.10 million and the lowest is $259.67 million. Opko Health reported sales of $263.50 million during the same quarter last year, which indicates a negative year-over-year growth rate of 0.4%. The firm is scheduled to issue its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Opko Health will report full year sales of $1.04 billion for the current year, with estimates ranging from $1.03 billion to $1.05 billion. For the next year, analysts anticipate that the company will report sales of $1.07 billion, with estimates ranging from $1.03 billion to $1.09 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Opko Health.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The firm had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million.
OPK traded down $0.08 during trading hours on Friday, hitting $3.59. 3,255,600 shares of the stock were exchanged, compared to its average volume of 5,552,234. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.99. The stock has a market capitalization of $2.13 billion, a PE ratio of -13.10 and a beta of 2.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90.
In related news, CEO Phillip Md Et Al Frost bought 55,000 shares of the company’s stock in a transaction on Tuesday, July 24th. The shares were purchased at an average cost of $5.60 per share, with a total value of $308,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $17,186,125.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders acquired 225,000 shares of company stock worth $1,210,850 over the last ninety days. 42.74% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. ING Groep NV acquired a new position in shares of Opko Health during the second quarter valued at $1,575,000. BlackRock Inc. grew its holdings in Opko Health by 38.7% during the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after acquiring an additional 8,237,434 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in Opko Health by 842.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 106,050 shares of the biotechnology company’s stock worth $498,000 after acquiring an additional 94,799 shares during the period. Rhumbline Advisers grew its holdings in Opko Health by 6.1% during the second quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock worth $1,585,000 after acquiring an additional 19,316 shares during the period. Finally, Northern Trust Corp grew its holdings in Opko Health by 4.0% during the first quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock worth $5,549,000 after acquiring an additional 66,562 shares during the period. 24.70% of the stock is currently owned by institutional investors.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Read More: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.